Supriya Lifescience Limited — Updates, 27-01-2025: Press Release (Revised)

In the third quarter of FY25, Supriya Lifescience reported significant financial growth, with revenues of Rs 185.65 Crore, marking a 33% increase year-over-year from Rs 140.07 Crore in Q3 FY24. The gross profit soared to Rs 123.87 Crore, up 45% from Rs 85.45 Crore the previous year. EBITDA for the quarter reached Rs 65.95 Crore, reflecting an improved EBITDA margin of 35.50%, compared to 29.60% a year earlier. Profit After Tax (PAT) demonstrated impressive growth, rising 57% to Rs 46.78 Crore, with a PAT margin of 25.2%. Chairman Dr. Satish Wagh highlighted the company's commitment to operational excellence and strategic initiatives, emphasizing the strong market presence and improved profitability metrics. With these results, the company showcases a positive outlook for sustained growth and competitive advantage in the pharmaceutical sector, warranting close attention from investors.